258 related articles for article (PubMed ID: 22348138)
21. First report and detailed characterization of B. pertussis isolates not expressing Pertussis Toxin or Pertactin.
Bouchez V; Brun D; Cantinelli T; Dore G; Njamkepo E; Guiso N
Vaccine; 2009 Oct; 27(43):6034-41. PubMed ID: 19666155
[TBL] [Abstract][Full Text] [Related]
22. Pertactin-Negative and Filamentous Hemagglutinin-Negative Bordetella pertussis, Australia, 2013-2017.
Xu Z; Octavia S; Luu LDW; Payne M; Timms V; Tay CY; Keil AD; Sintchenko V; Guiso N; Lan R
Emerg Infect Dis; 2019 Jun; 25(6):1196-1199. PubMed ID: 31107218
[TBL] [Abstract][Full Text] [Related]
23. Pertactin negative Bordetella pertussis demonstrates higher fitness under vaccine selection pressure in a mixed infection model.
Safarchi A; Octavia S; Luu LD; Tay CY; Sintchenko V; Wood N; Marshall H; McIntyre P; Lan R
Vaccine; 2015 Nov; 33(46):6277-81. PubMed ID: 26432908
[TBL] [Abstract][Full Text] [Related]
24. Construction of Bordetella pertussis strains with enhanced production of genetically-inactivated Pertussis Toxin and Pertactin by unmarked allelic exchange.
Buasri W; Impoolsup A; Boonchird C; Luengchaichawange A; Prompiboon P; Petre J; Panbangred W
BMC Microbiol; 2012 Apr; 12():61. PubMed ID: 22524455
[TBL] [Abstract][Full Text] [Related]
25. Analysis of Bordetella pertussis pertactin and pertussis toxin types from Queensland, Australia, 1999-2003.
Byrne S; Slack AT
BMC Infect Dis; 2006 Mar; 6():53. PubMed ID: 16542440
[TBL] [Abstract][Full Text] [Related]
26. Polymorphism in Bordetella pertussis pertactin and pertussis toxin virulence factors in the United States, 1935-1999.
Cassiday P; Sanden G; Heuvelman K; Mooi F; Bisgard KM; Popovic T
J Infect Dis; 2000 Nov; 182(5):1402-8. PubMed ID: 11023463
[TBL] [Abstract][Full Text] [Related]
27. Rapid identification of Bordetella pertussis pertactin gene variants using LightCycler real-time polymerase chain reaction combined with melting curve analysis and gel electrophoresis.
Mäkinen J; Viljanen MK; Mertsola J; Arvilommi H; He Q
Emerg Infect Dis; 2001; 7(6):952-8. PubMed ID: 11747721
[TBL] [Abstract][Full Text] [Related]
28. Screening and Genomic Characterization of Filamentous Hemagglutinin-Deficient Bordetella pertussis.
Weigand MR; Pawloski LC; Peng Y; Ju H; Burroughs M; Cassiday PK; Davis JK; DuVall M; Johnson T; Juieng P; Knipe K; Loparev VN; Mathis MH; Rowe LA; Sheth M; Williams MM; Tondella ML
Infect Immun; 2018 Apr; 86(4):. PubMed ID: 29358336
[TBL] [Abstract][Full Text] [Related]
29. Genetic analysis of Bordetella pertussis isolates from the 2008-2010 pertussis epidemic in Japan.
Miyaji Y; Otsuka N; Toyoizumi-Ajisaka H; Shibayama K; Kamachi K
PLoS One; 2013; 8(10):e77165. PubMed ID: 24124606
[TBL] [Abstract][Full Text] [Related]
30. Virulence of pertactin-negative Bordetella pertussis isolates from infants, France.
Bodilis H; Guiso N
Emerg Infect Dis; 2013 Mar; 19(3):471-4. PubMed ID: 23621904
[TBL] [Abstract][Full Text] [Related]
31. Studies on Prn variation in the mouse model and comparison with epidemiological data.
van Gent M; van Loo IH; Heuvelman KJ; de Neeling AJ; Teunis P; Mooi FR
PLoS One; 2011 Mar; 6(3):e18014. PubMed ID: 21464955
[TBL] [Abstract][Full Text] [Related]
32. Simple Algorithm for Identification of Bordetella pertussis Pertactin Gene Variants.
Muyldermans G; Piérard D; Hoebrekx N; Advani R; Van Amersfoorth S; De Schutter I; Soetens O; Eeckhout L; Malfroot A; Lauwers S
J Clin Microbiol; 2004 Apr; 42(4):1614-9. PubMed ID: 15071014
[TBL] [Abstract][Full Text] [Related]
33. Bordetella pertussis and pertactin-deficient clinical isolates: lessons for pertussis vaccines.
Hegerle N; Guiso N
Expert Rev Vaccines; 2014 Sep; 13(9):1135-46. PubMed ID: 24953157
[TBL] [Abstract][Full Text] [Related]
34. Pertactin deficient Bordetella pertussis present a better fitness in mice immunized with an acellular pertussis vaccine.
Hegerle N; Dore G; Guiso N
Vaccine; 2014 Nov; 32(49):6597-600. PubMed ID: 25312274
[TBL] [Abstract][Full Text] [Related]
35. The relationship between Bordetella pertussis genotype and clinical severity in Australian children with pertussis.
Clarke M; McIntyre PB; Blyth CC; Wood N; Octavia S; Sintchenko V; Giles L; Quinn H; Hill V; Hanly G; Lan R; Marshall HS
J Infect; 2016 Feb; 72(2):171-8. PubMed ID: 26675318
[TBL] [Abstract][Full Text] [Related]
36. Evolution of French Bordetella pertussis and Bordetella parapertussis isolates: increase of Bordetellae not expressing pertactin.
Hegerle N; Paris AS; Brun D; Dore G; Njamkepo E; Guillot S; Guiso N
Clin Microbiol Infect; 2012 Sep; 18(9):E340-6. PubMed ID: 22717007
[TBL] [Abstract][Full Text] [Related]
37. Synergic effect of genotype changes in pertussis toxin and pertactin on adaptation to an acellular pertussis vaccine in the murine intranasal challenge model.
Komatsu E; Yamaguchi F; Abe A; Weiss AA; Watanabe M
Clin Vaccine Immunol; 2010 May; 17(5):807-12. PubMed ID: 20357056
[TBL] [Abstract][Full Text] [Related]
38. The importance of Bordetella pertussis strains which do not produce virulence factors in the epidemiology of pertussis.
Polak M; Lutyńska A
Postepy Hig Med Dosw (Online); 2017 May; 71(0):367-379. PubMed ID: 28513461
[TBL] [Abstract][Full Text] [Related]
39. Molecular epidemiology of the pertussis epidemic in Washington State in 2012.
Bowden KE; Williams MM; Cassiday PK; Milton A; Pawloski L; Harrison M; Martin SW; Meyer S; Qin X; DeBolt C; Tasslimi A; Syed N; Sorrell R; Tran M; Hiatt B; Tondella ML
J Clin Microbiol; 2014 Oct; 52(10):3549-57. PubMed ID: 25031439
[TBL] [Abstract][Full Text] [Related]
40. Genotypic variation in the Bordetella pertussis virulence factors pertactin and pertussis toxin in historical and recent clinical isolates in the United Kingdom.
Fry NK; Neal S; Harrison TG; Miller E; Matthews R; George RC
Infect Immun; 2001 Sep; 69(9):5520-8. PubMed ID: 11500425
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
